drugset
drugset / Trial / NCT06125041

Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC

NCT06125041 ↗

Phase 2 Recruiting 51 enrolled Qianfoshan Hospital
NaSingle-groupOpen-labelTreatment

Summary

To observe the efficacy and safety of adebelizumab combined with chemotherapy and sequential adebelizumab combined with radiotherapy in the treatment of newly diagnosed extensive small cell lung cancer.

Timeline

Start
2023-10-30
Primary completion
2026-07-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebelizumab Unknown 20 mg/kg Intravenous
Background Carboplatin Small molecule 5 unknown —
Background Etoposide Small molecule 100 mg/m2 —

Indications

small cell lung carcinoma